ID   PKN3_HUMAN              Reviewed;         889 AA.
AC   Q6P5Z2; Q9UM03;
DT   25-OCT-2005, integrated into UniProtKB/Swiss-Prot.
DT   05-JUL-2004, sequence version 1.
DT   12-OCT-2022, entry version 176.
DE   RecName: Full=Serine/threonine-protein kinase N3;
DE            EC=2.7.11.13;
DE   AltName: Full=Protein kinase PKN-beta;
DE   AltName: Full=Protein-kinase C-related kinase 3;
GN   Name=PKN3; Synonyms=PKNBETA;
OS   Homo sapiens (Human).
OC   Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia;
OC   Eutheria; Euarchontoglires; Primates; Haplorrhini; Catarrhini; Hominidae;
OC   Homo.
OX   NCBI_TaxID=9606;
RN   [1]
RP   NUCLEOTIDE SEQUENCE [MRNA], AUTOPHOSPHORYLATION, MUTAGENESIS OF LYS-588,
RP   SUBCELLULAR LOCATION, AND TISSUE SPECIFICITY.
RC   TISSUE=Cervix carcinoma;
RX   PubMed=10441506; DOI=10.1006/bbrc.1999.1116;
RA   Oishi K., Mukai H., Shibata H., Takahashi M., Ono Y.;
RT   "Identification and characterization of PKNbeta, a novel isoform of protein
RT   kinase PKN: expression and arachidonic acid dependency are different from
RT   those of PKNalpha.";
RL   Biochem. Biophys. Res. Commun. 261:808-814(1999).
RN   [2]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA].
RX   PubMed=15164053; DOI=10.1038/nature02465;
RA   Humphray S.J., Oliver K., Hunt A.R., Plumb R.W., Loveland J.E., Howe K.L.,
RA   Andrews T.D., Searle S., Hunt S.E., Scott C.E., Jones M.C., Ainscough R.,
RA   Almeida J.P., Ambrose K.D., Ashwell R.I.S., Babbage A.K., Babbage S.,
RA   Bagguley C.L., Bailey J., Banerjee R., Barker D.J., Barlow K.F., Bates K.,
RA   Beasley H., Beasley O., Bird C.P., Bray-Allen S., Brown A.J., Brown J.Y.,
RA   Burford D., Burrill W., Burton J., Carder C., Carter N.P., Chapman J.C.,
RA   Chen Y., Clarke G., Clark S.Y., Clee C.M., Clegg S., Collier R.E.,
RA   Corby N., Crosier M., Cummings A.T., Davies J., Dhami P., Dunn M.,
RA   Dutta I., Dyer L.W., Earthrowl M.E., Faulkner L., Fleming C.J.,
RA   Frankish A., Frankland J.A., French L., Fricker D.G., Garner P.,
RA   Garnett J., Ghori J., Gilbert J.G.R., Glison C., Grafham D.V., Gribble S.,
RA   Griffiths C., Griffiths-Jones S., Grocock R., Guy J., Hall R.E.,
RA   Hammond S., Harley J.L., Harrison E.S.I., Hart E.A., Heath P.D.,
RA   Henderson C.D., Hopkins B.L., Howard P.J., Howden P.J., Huckle E.,
RA   Johnson C., Johnson D., Joy A.A., Kay M., Keenan S., Kershaw J.K.,
RA   Kimberley A.M., King A., Knights A., Laird G.K., Langford C., Lawlor S.,
RA   Leongamornlert D.A., Leversha M., Lloyd C., Lloyd D.M., Lovell J.,
RA   Martin S., Mashreghi-Mohammadi M., Matthews L., McLaren S., McLay K.E.,
RA   McMurray A., Milne S., Nickerson T., Nisbett J., Nordsiek G., Pearce A.V.,
RA   Peck A.I., Porter K.M., Pandian R., Pelan S., Phillimore B., Povey S.,
RA   Ramsey Y., Rand V., Scharfe M., Sehra H.K., Shownkeen R., Sims S.K.,
RA   Skuce C.D., Smith M., Steward C.A., Swarbreck D., Sycamore N., Tester J.,
RA   Thorpe A., Tracey A., Tromans A., Thomas D.W., Wall M., Wallis J.M.,
RA   West A.P., Whitehead S.L., Willey D.L., Williams S.A., Wilming L.,
RA   Wray P.W., Young L., Ashurst J.L., Coulson A., Blocker H., Durbin R.M.,
RA   Sulston J.E., Hubbard T., Jackson M.J., Bentley D.R., Beck S., Rogers J.,
RA   Dunham I.;
RT   "DNA sequence and analysis of human chromosome 9.";
RL   Nature 429:369-374(2004).
RN   [3]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA].
RC   TISSUE=Ovary;
RX   PubMed=15489334; DOI=10.1101/gr.2596504;
RG   The MGC Project Team;
RT   "The status, quality, and expansion of the NIH full-length cDNA project:
RT   the Mammalian Gene Collection (MGC).";
RL   Genome Res. 14:2121-2127(2004).
RN   [4]
RP   FUNCTION IN MALIGNANT CELL GROWTH, PHOSPHORYLATION AT THR-718, AND
RP   MUTAGENESIS OF LYS-588 AND THR-718.
RX   PubMed=15282551; DOI=10.1038/sj.emboj.7600345;
RA   Leenders F., Moepert K., Schmiedeknecht A., Santel A., Czauderna F.,
RA   Aleku M., Penschuck S., Dames S., Sternberger M., Roehl T., Wellmann A.,
RA   Arnold W., Giese K., Kaufmann J., Klippel A.;
RT   "PKN3 is required for malignant prostate cell growth downstream of
RT   activated PI 3-kinase.";
RL   EMBO J. 23:3303-3313(2004).
RN   [5]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-544; THR-722 AND THR-860, AND
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Cervix carcinoma;
RX   PubMed=18691976; DOI=10.1016/j.molcel.2008.07.007;
RA   Daub H., Olsen J.V., Bairlein M., Gnad F., Oppermann F.S., Korner R.,
RA   Greff Z., Keri G., Stemmann O., Mann M.;
RT   "Kinase-selective enrichment enables quantitative phosphoproteomics of the
RT   kinome across the cell cycle.";
RL   Mol. Cell 31:438-448(2008).
RN   [6]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-544 AND SER-548, AND
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Cervix carcinoma;
RX   PubMed=18669648; DOI=10.1073/pnas.0805139105;
RA   Dephoure N., Zhou C., Villen J., Beausoleil S.A., Bakalarski C.E.,
RA   Elledge S.J., Gygi S.P.;
RT   "A quantitative atlas of mitotic phosphorylation.";
RL   Proc. Natl. Acad. Sci. U.S.A. 105:10762-10767(2008).
RN   [7]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-544 AND THR-860, AND
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RX   PubMed=19369195; DOI=10.1074/mcp.m800588-mcp200;
RA   Oppermann F.S., Gnad F., Olsen J.V., Hornberger R., Greff Z., Keri G.,
RA   Mann M., Daub H.;
RT   "Large-scale proteomics analysis of the human kinome.";
RL   Mol. Cell. Proteomics 8:1751-1764(2009).
RN   [8]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-171 AND SER-544, AND
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Cervix carcinoma, and Erythroleukemia;
RX   PubMed=23186163; DOI=10.1021/pr300630k;
RA   Zhou H., Di Palma S., Preisinger C., Peng M., Polat A.N., Heck A.J.,
RA   Mohammed S.;
RT   "Toward a comprehensive characterization of a human cancer cell
RT   phosphoproteome.";
RL   J. Proteome Res. 12:260-271(2013).
RN   [9]
RP   VARIANT [LARGE SCALE ANALYSIS] GLU-180.
RX   PubMed=17344846; DOI=10.1038/nature05610;
RA   Greenman C., Stephens P., Smith R., Dalgliesh G.L., Hunter C., Bignell G.,
RA   Davies H., Teague J., Butler A., Stevens C., Edkins S., O'Meara S.,
RA   Vastrik I., Schmidt E.E., Avis T., Barthorpe S., Bhamra G., Buck G.,
RA   Choudhury B., Clements J., Cole J., Dicks E., Forbes S., Gray K.,
RA   Halliday K., Harrison R., Hills K., Hinton J., Jenkinson A., Jones D.,
RA   Menzies A., Mironenko T., Perry J., Raine K., Richardson D., Shepherd R.,
RA   Small A., Tofts C., Varian J., Webb T., West S., Widaa S., Yates A.,
RA   Cahill D.P., Louis D.N., Goldstraw P., Nicholson A.G., Brasseur F.,
RA   Looijenga L., Weber B.L., Chiew Y.-E., DeFazio A., Greaves M.F.,
RA   Green A.R., Campbell P., Birney E., Easton D.F., Chenevix-Trench G.,
RA   Tan M.-H., Khoo S.K., Teh B.T., Yuen S.T., Leung S.Y., Wooster R.,
RA   Futreal P.A., Stratton M.R.;
RT   "Patterns of somatic mutation in human cancer genomes.";
RL   Nature 446:153-158(2007).
CC   -!- FUNCTION: Contributes to invasiveness in malignant prostate cancer.
CC       {ECO:0000269|PubMed:15282551}.
CC   -!- CATALYTIC ACTIVITY:
CC       Reaction=ATP + L-seryl-[protein] = ADP + H(+) + O-phospho-L-seryl-
CC         [protein]; Xref=Rhea:RHEA:17989, Rhea:RHEA-COMP:9863, Rhea:RHEA-
CC         COMP:11604, ChEBI:CHEBI:15378, ChEBI:CHEBI:29999, ChEBI:CHEBI:30616,
CC         ChEBI:CHEBI:83421, ChEBI:CHEBI:456216; EC=2.7.11.13;
CC   -!- CATALYTIC ACTIVITY:
CC       Reaction=ATP + L-threonyl-[protein] = ADP + H(+) + O-phospho-L-
CC         threonyl-[protein]; Xref=Rhea:RHEA:46608, Rhea:RHEA-COMP:11060,
CC         Rhea:RHEA-COMP:11605, ChEBI:CHEBI:15378, ChEBI:CHEBI:30013,
CC         ChEBI:CHEBI:30616, ChEBI:CHEBI:61977, ChEBI:CHEBI:456216;
CC         EC=2.7.11.13;
CC   -!- ACTIVITY REGULATION: Two specific sites, Thr-718 (activation loop of
CC       the kinase domain) and Thr-860 (turn motif), need to be phosphorylated
CC       for its full activation. {ECO:0000250}.
CC   -!- INTERACTION:
CC       Q6P5Z2; A1A4S6: ARHGAP10; NbExp=5; IntAct=EBI-1384335, EBI-1390944;
CC       Q6P5Z2; Q9UNA1: ARHGAP26; NbExp=5; IntAct=EBI-1384335, EBI-1390913;
CC       Q6P5Z2; Q08379: GOLGA2; NbExp=3; IntAct=EBI-1384335, EBI-618309;
CC       Q6P5Z2; Q15323: KRT31; NbExp=3; IntAct=EBI-1384335, EBI-948001;
CC       Q6P5Z2; Q5JR59-3: MTUS2; NbExp=3; IntAct=EBI-1384335, EBI-11522433;
CC       Q6P5Z2; Q8ND90: PNMA1; NbExp=3; IntAct=EBI-1384335, EBI-302345;
CC       Q6P5Z2; Q9UBB9: TFIP11; NbExp=3; IntAct=EBI-1384335, EBI-1105213;
CC       Q6P5Z2; Q8N1B4: VPS52; NbExp=3; IntAct=EBI-1384335, EBI-2799833;
CC   -!- SUBCELLULAR LOCATION: Nucleus {ECO:0000269|PubMed:10441506}. Cytoplasm,
CC       perinuclear region {ECO:0000269|PubMed:10441506}. Note=Nuclear and
CC       perinuclear Golgi region.
CC   -!- TISSUE SPECIFICITY: Expressed in prostate tumors and various cancer
CC       cell lines. Not expressed in adult tissues.
CC       {ECO:0000269|PubMed:10441506}.
CC   -!- DOMAIN: The C1 domain does not bind the diacylglycerol (DAG).
CC   -!- PTM: Autophosphorylated. {ECO:0000269|PubMed:15282551}.
CC   -!- SIMILARITY: Belongs to the protein kinase superfamily. AGC Ser/Thr
CC       protein kinase family. PKC subfamily. {ECO:0000305}.
CC   ---------------------------------------------------------------------------
CC   Copyrighted by the UniProt Consortium, see https://www.uniprot.org/terms
CC   Distributed under the Creative Commons Attribution (CC BY 4.0) License
CC   ---------------------------------------------------------------------------
DR   EMBL; AB019692; BAA85625.1; -; mRNA.
DR   EMBL; AL441992; -; NOT_ANNOTATED_CDS; Genomic_DNA.
DR   EMBL; BC062558; AAH62558.1; -; mRNA.
DR   CCDS; CCDS6908.1; -.
DR   PIR; JC7083; JC7083.
DR   RefSeq; NP_037487.2; NM_013355.4.
DR   AlphaFoldDB; Q6P5Z2; -.
DR   SMR; Q6P5Z2; -.
DR   BioGRID; 118978; 136.
DR   IntAct; Q6P5Z2; 110.
DR   MINT; Q6P5Z2; -.
DR   STRING; 9606.ENSP00000291906; -.
DR   BindingDB; Q6P5Z2; -.
DR   ChEMBL; CHEMBL3627581; -.
DR   iPTMnet; Q6P5Z2; -.
DR   PhosphoSitePlus; Q6P5Z2; -.
DR   BioMuta; PKN3; -.
DR   DMDM; 74749130; -.
DR   EPD; Q6P5Z2; -.
DR   jPOST; Q6P5Z2; -.
DR   MassIVE; Q6P5Z2; -.
DR   MaxQB; Q6P5Z2; -.
DR   PaxDb; Q6P5Z2; -.
DR   PeptideAtlas; Q6P5Z2; -.
DR   PRIDE; Q6P5Z2; -.
DR   ProteomicsDB; 67014; -.
DR   Antibodypedia; 31249; 192 antibodies from 28 providers.
DR   DNASU; 29941; -.
DR   Ensembl; ENST00000291906.5; ENSP00000291906.4; ENSG00000160447.7.
DR   GeneID; 29941; -.
DR   KEGG; hsa:29941; -.
DR   MANE-Select; ENST00000291906.5; ENSP00000291906.4; NM_013355.5; NP_037487.2.
DR   UCSC; uc004bvw.4; human.
DR   CTD; 29941; -.
DR   DisGeNET; 29941; -.
DR   GeneCards; PKN3; -.
DR   HGNC; HGNC:17999; PKN3.
DR   HPA; ENSG00000160447; Low tissue specificity.
DR   MIM; 610714; gene.
DR   neXtProt; NX_Q6P5Z2; -.
DR   OpenTargets; ENSG00000160447; -.
DR   PharmGKB; PA134919098; -.
DR   VEuPathDB; HostDB:ENSG00000160447; -.
DR   eggNOG; KOG0694; Eukaryota.
DR   GeneTree; ENSGT00940000161818; -.
DR   HOGENOM; CLU_000288_132_1_1; -.
DR   InParanoid; Q6P5Z2; -.
DR   OMA; NMNVAAW; -.
DR   OrthoDB; 520651at2759; -.
DR   PhylomeDB; Q6P5Z2; -.
DR   TreeFam; TF102005; -.
DR   PathwayCommons; Q6P5Z2; -.
DR   Reactome; R-HSA-5625740; RHO GTPases activate PKNs.
DR   Reactome; R-HSA-8980692; RHOA GTPase cycle.
DR   Reactome; R-HSA-9013026; RHOB GTPase cycle.
DR   Reactome; R-HSA-9013106; RHOC GTPase cycle.
DR   SignaLink; Q6P5Z2; -.
DR   SIGNOR; Q6P5Z2; -.
DR   BioGRID-ORCS; 29941; 20 hits in 1112 CRISPR screens.
DR   ChiTaRS; PKN3; human.
DR   GeneWiki; PKN3_(gene); -.
DR   GenomeRNAi; 29941; -.
DR   Pharos; Q6P5Z2; Tchem.
DR   PRO; PR:Q6P5Z2; -.
DR   Proteomes; UP000005640; Chromosome 9.
DR   RNAct; Q6P5Z2; protein.
DR   Bgee; ENSG00000160447; Expressed in apex of heart and 109 other tissues.
DR   ExpressionAtlas; Q6P5Z2; baseline and differential.
DR   Genevisible; Q6P5Z2; HS.
DR   GO; GO:0005829; C:cytosol; TAS:Reactome.
DR   GO; GO:0005794; C:Golgi apparatus; TAS:ProtInc.
DR   GO; GO:0005634; C:nucleus; TAS:ProtInc.
DR   GO; GO:0048471; C:perinuclear region of cytoplasm; IEA:UniProtKB-SubCell.
DR   GO; GO:0005524; F:ATP binding; IEA:UniProtKB-KW.
DR   GO; GO:0004698; F:calcium-dependent protein kinase C activity; IEA:UniProtKB-EC.
DR   GO; GO:0004672; F:protein kinase activity; TAS:ProtInc.
DR   GO; GO:0106310; F:protein serine kinase activity; IEA:RHEA.
DR   GO; GO:0004674; F:protein serine/threonine kinase activity; IBA:GO_Central.
DR   GO; GO:0031267; F:small GTPase binding; IEA:InterPro.
DR   GO; GO:0010631; P:epithelial cell migration; IDA:UniProtKB.
DR   GO; GO:0035556; P:intracellular signal transduction; IBA:GO_Central.
DR   GO; GO:0018105; P:peptidyl-serine phosphorylation; IBA:GO_Central.
DR   GO; GO:0006468; P:protein phosphorylation; TAS:ProtInc.
DR   GO; GO:0007165; P:signal transduction; TAS:ProtInc.
DR   CDD; cd11622; HR1_PKN_1; 1.
DR   InterPro; IPR000961; AGC-kinase_C.
DR   InterPro; IPR035892; C2_domain_sf.
DR   InterPro; IPR011072; HR1_rho-bd.
DR   InterPro; IPR036274; HR1_rpt_sf.
DR   InterPro; IPR011009; Kinase-like_dom_sf.
DR   InterPro; IPR017892; Pkinase_C.
DR   InterPro; IPR037313; PKN_HR1_1.
DR   InterPro; IPR000719; Prot_kinase_dom.
DR   InterPro; IPR017441; Protein_kinase_ATP_BS.
DR   InterPro; IPR008271; Ser/Thr_kinase_AS.
DR   Pfam; PF02185; HR1; 3.
DR   Pfam; PF00069; Pkinase; 1.
DR   Pfam; PF00433; Pkinase_C; 1.
DR   SMART; SM00742; Hr1; 3.
DR   SMART; SM00133; S_TK_X; 1.
DR   SMART; SM00220; S_TKc; 1.
DR   SUPFAM; SSF46585; SSF46585; 3.
DR   SUPFAM; SSF49562; SSF49562; 1.
DR   SUPFAM; SSF56112; SSF56112; 1.
DR   PROSITE; PS51285; AGC_KINASE_CTER; 1.
DR   PROSITE; PS00107; PROTEIN_KINASE_ATP; 1.
DR   PROSITE; PS50011; PROTEIN_KINASE_DOM; 1.
DR   PROSITE; PS00108; PROTEIN_KINASE_ST; 1.
DR   PROSITE; PS51860; REM_1; 3.
PE   1: Evidence at protein level;
KW   ATP-binding; Coiled coil; Cytoplasm; Kinase; Nucleotide-binding; Nucleus;
KW   Phosphoprotein; Reference proteome; Repeat;
KW   Serine/threonine-protein kinase; Transferase.
FT   CHAIN           1..889
FT                   /note="Serine/threonine-protein kinase N3"
FT                   /id="PRO_0000055725"
FT   DOMAIN          5..80
FT                   /note="REM-1 1"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU01207"
FT   DOMAIN          93..163
FT                   /note="REM-1 2"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU01207"
FT   DOMAIN          165..245
FT                   /note="REM-1 3"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU01207"
FT   DOMAIN          559..818
FT                   /note="Protein kinase"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00159"
FT   DOMAIN          819..889
FT                   /note="AGC-kinase C-terminal"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00618"
FT   REGION          468..555
FT                   /note="Disordered"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   COMPBIAS        504..518
FT                   /note="Pro residues"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   COMPBIAS        525..539
FT                   /note="Basic and acidic residues"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   ACT_SITE        684
FT                   /note="Proton acceptor"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00159,
FT                   ECO:0000255|PROSITE-ProRule:PRU10027"
FT   BINDING         565..573
FT                   /ligand="ATP"
FT                   /ligand_id="ChEBI:CHEBI:30616"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00159"
FT   BINDING         588
FT                   /ligand="ATP"
FT                   /ligand_id="ChEBI:CHEBI:30616"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00159"
FT   MOD_RES         171
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0007744|PubMed:23186163"
FT   MOD_RES         544
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0007744|PubMed:18669648,
FT                   ECO:0007744|PubMed:18691976, ECO:0007744|PubMed:19369195,
FT                   ECO:0007744|PubMed:23186163"
FT   MOD_RES         548
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0007744|PubMed:18669648"
FT   MOD_RES         718
FT                   /note="Phosphothreonine"
FT                   /evidence="ECO:0000269|PubMed:15282551"
FT   MOD_RES         722
FT                   /note="Phosphothreonine"
FT                   /evidence="ECO:0007744|PubMed:18691976"
FT   MOD_RES         860
FT                   /note="Phosphothreonine"
FT                   /evidence="ECO:0007744|PubMed:18691976,
FT                   ECO:0007744|PubMed:19369195"
FT   VARIANT         180
FT                   /note="A -> E (in dbSNP:rs56251280)"
FT                   /evidence="ECO:0000269|PubMed:17344846"
FT                   /id="VAR_042346"
FT   VARIANT         404
FT                   /note="V -> L (in dbSNP:rs12932)"
FT                   /id="VAR_050565"
FT   MUTAGEN         588
FT                   /note="K->E: Abolishes autophosphorylation and catalytic
FT                   activity."
FT                   /evidence="ECO:0000269|PubMed:10441506,
FT                   ECO:0000269|PubMed:15282551"
FT   MUTAGEN         588
FT                   /note="K->R: Abolishes catalytic activity."
FT                   /evidence="ECO:0000269|PubMed:10441506,
FT                   ECO:0000269|PubMed:15282551"
FT   MUTAGEN         718
FT                   /note="T->A: Abolishes phosphorylation."
FT                   /evidence="ECO:0000269|PubMed:15282551"
FT   CONFLICT        444
FT                   /note="A -> R (in Ref. 1; BAA85625)"
FT                   /evidence="ECO:0000305"
FT   CONFLICT        627
FT                   /note="A -> V (in Ref. 1; BAA85625)"
FT                   /evidence="ECO:0000305"
FT   CONFLICT        636
FT                   /note="C -> R (in Ref. 1; BAA85625)"
FT                   /evidence="ECO:0000305"
FT   CONFLICT        738
FT                   /note="R -> Q (in Ref. 1; BAA85625)"
FT                   /evidence="ECO:0000305"
FT   CONFLICT        744
FT                   /note="G -> A (in Ref. 1; BAA85625)"
FT                   /evidence="ECO:0000305"
SQ   SEQUENCE   889 AA;  99421 MW;  F3891DA1420DF54E CRC64;
     MEEGAPRQPG PSQWPPEDEK EVIRRAIQKE LKIKEGVENL RRVATDRRHL GHVQQLLRSS
     NRRLEQLHGE LRELHARILL PGPGPGPAEP VASGPRPWAE QLRARHLEAL RRQLHVELKV
     KQGAENMTHT CASGTPKERK LLAAAQQMLR DSQLKVALLR MKISSLEASG SPEPGPELLA
     EELQHRLHVE AAVAEGAKNV VKLLSSRRTQ DRKALAEAQA QLQESSQKLD LLRLALEQLL
     EQLPPAHPLR SRVTRELRAA VPGYPQPSGT PVKPTALTGT LQVRLLGCEQ LLTAVPGRSP
     AAALASSPSE GWLRTKAKHQ RGRGELASEV LAVLKVDNRV VGQTGWGQVA EQSWDQTFVI
     PLERARELEI GVHWRDWRQL CGVAFLRLED FLDNACHQLS LSLVPQGLLF AQVTFCDPVI
     ERRPRLQRQE RIFSKRRGQD FLRASQMNLG MAAWGRLVMN LLPPCSSPST ISPPKGCPRT
     PTTLREASDP ATPSNFLPKK TPLGEEMTPP PKPPRLYLPQ EPTSEETPRT KRPHMEPRTR
     RGPSPPASPT RKPPRLQDFR CLAVLGRGHF GKVLLVQFKG TGKYYAIKAL KKQEVLSRDE
     IESLYCEKRI LEAVGCTGHP FLLSLLACFQ TSSHACFVTE FVPGGDLMMQ IHEDVFPEPQ
     ARFYVACVVL GLQFLHEKKI IYRDLKLDNL LLDAQGFLKI ADFGLCKEGI GFGDRTSTFC
     GTPEFLAPEV LTQEAYTRAV DWWGLGVLLY EMLVGECPFP GDTEEEVFDC IVNMDAPYPG
     FLSVQGLEFI QKLLQKCPEK RLGAGEQDAE EIKVQPFFRT TNWQALLART IQPPFVPTLC
     GPADLRYFEG EFTGLPPALT PPAPHSLLTA RQQAAFRDFD FVSERFLEP
//
